Treatment Resistant Depression Pipeline Analysis 2024: FDA Approvals and Emerging Therapies, Mechanism of Action, Route of Administration by DelveInsight | Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech,

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Treatment Resistant Depression pipeline constitutes 25+ key companies continuously working towards developing 25+ Treatment Resistant Depression treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Treatment Resistant Depression Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Treatment Resistant Depression Market.

The Treatment Resistant Depression Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Treatment Resistant Depression Pipeline Report: https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Treatment Resistant Depression treatment therapies with a considerable amount of success over the years.
• Treatment Resistant Depression companies working in the treatment market are GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, COMPASS Pathways, Mapreg, Sound Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Merck Sharp & Dohme, Novartis, Denovo Biopharma LLC, COMPASS Pathways, Navitor Pharmaceuticals, Supernus Pharmaceuticals, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others, are developing therapies for the Treatment Resistant Depression treatment
• Emerging Treatment Resistant Depression therapies in the different phases of clinical trials are- GH001, VLS-01-203 BU, BPL-003, Psilocybin, MAP4343, Ebselen, HS-10345, MK-1942, MIJ821, Liafensine, Psilocybin, NV5138, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others are expected to have a significant impact on the Treatment Resistant Depression market in the coming years.
• In April 2024, The US Food and Drug Administration (FDA) has given approval to Freedom Biosciences' investigational new drug (IND) application for FREE001, allowing the start of its Phase IIa clinical trial for the ketamine-based combination therapy aimed at treating treatment-resistant depression (TRD). The trial, named FREE001-TRD-201, is scheduled to begin in the first half of this year and marks a notable step forward in addressing the unmet needs of TRD patients. FREE001, the company's lead program, combines ketamine with temsirolimus and is being developed as an additional therapy for adults with TRD who have not responded sufficiently to at least two antidepressant treatments.
• In February 2023, COMPASS Pathways has commenced a Phase III clinical trial, a multicenter, randomized, double-blind, controlled study designed to explore the effectiveness, safety, and tolerance of two doses of COMP360 in individuals diagnosed with Treatment-resistant Depression. The main objective of this trial is to assess the change in MADRS (Montgomery-Åsberg Depression Rating Scale) total score from baseline, comparing COMP360 25 mg against COMP360 1 mg as the primary endpoint.
• In July 2022, Abbott has obtained approval from the United States Food and Drug Administration (FDA) to utilize its deep brain stimulation (DBS) device in treating individuals with treatment-resistant depression (TRD).

Treatment Resistant Depression Overview
Treatment-resistant depression (TRD) refers to a form of depression that does not adequately respond to multiple standard treatments. Individuals diagnosed with TRD continue to experience depressive symptoms despite having undergone various therapies, which might include different antidepressant medications, psychotherapy, or other standard treatments for depression.

Get a Free Sample PDF Report to know more about Treatment Resistant Depression Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Treatment Resistant Depression Drugs Under Different Phases of Clinical Development Include:
• GH001: GH Research Ireland Limited
• VLS-01-203 BU: atai Therapeutics, Inc.
• BPL-003: Beckley Psytech Limited
• Psilocybin: COMPASS Pathways
• MAP4343: Mapreg
• Ebselen: Sound Pharmaceuticals
• HS-10345: Jiangsu Hansoh Pharmaceutical
• MK-1942: Merck Sharp & Dohme
• MIJ821: Novartis
• Liafensine: Denovo Biopharma LLC
• Psilocybin: COMPASS Pathways
• NV5138: Navitor Pharmaceuticals/Supernus Pharmaceuticals
• REL-1017: Relmada Therapeutics
• BPL-003: Beckley Psytech
• COMP360 (Psilocybin): COMPASS Pathways
• AXS-05: Axsome Therapeutics
• FALKIERI (esketamine DPI): Celon Pharma

Treatment Resistant Depression Route of Administration
Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Treatment Resistant Depression Molecule Type
Treatment Resistant Depression Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Treatment Resistant Depression Pipeline Therapeutics Assessment
• Treatment Resistant Depression Assessment by Product Type
• Treatment Resistant Depression By Stage and Product Type
• Treatment Resistant Depression Assessment by Route of Administration
• Treatment Resistant Depression By Stage and Route of Administration
• Treatment Resistant Depression Assessment by Molecule Type
• Treatment Resistant Depression by Stage and Molecule Type

DelveInsight's Treatment Resistant Depression Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Treatment Resistant Depression product details are provided in the report. Download the Treatment Resistant Depression pipeline report to learn more about the emerging Treatment Resistant Depression therapies at:
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Treatment Resistant Depression Therapeutics Market include:
Key companies developing therapies for Treatment Resistant Depression are - Navitor Pharmaceuticals, Supernus Pharmaceuticals, Novartis, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others.

Treatment Resistant Depression Pipeline Analysis:
The Treatment Resistant Depression pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Treatment Resistant Depression with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Treatment Resistant Depression Treatment.
• Treatment Resistant Depression key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Treatment Resistant Depression Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Treatment Resistant Depression market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Treatment Resistant Depression drugs and therapies-
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Treatment Resistant Depression Pipeline Market Drivers
• Increasing Prevalence of Treatment Resistant Depression increase in Research and Developmental activities for the treatment of Treatment Resistant Depression are some of the important factors that are fueling the Treatment Resistant Depression Market.

Treatment Resistant Depression Pipeline Market Barriers
• However, side-effects associated with the treatment of Treatment Resistant Depression, poor management of Treatment Resistant Depression and other factors are creating obstacles in the Treatment Resistant Depression Market growth.

Scope of Treatment Resistant Depression Pipeline Drug Insight
• Coverage: Global
• Key Treatment Resistant Depression Companies: GH Research Ireland Limited, atai Therapeutics, Inc., Beckley Psytech Limited, COMPASS Pathways, Mapreg, Sound Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Merck Sharp & Dohme, Novartis, Denovo Biopharma LLC, COMPASS Pathways, Navitor Pharmaceuticals, Supernus Pharmaceuticals, Relmada Therapeutics, Beckley Psytech, COMPASS Pathways, Axsome Therapeutics, Celon Pharma, and others
• Key Treatment Resistant Depression Therapies: GH001, VLS-01-203 BU, BPL-003, Psilocybin, MAP4343, Ebselen, HS-10345, MK-1942, MIJ821, Liafensine, Psilocybin, NV5138, REL-1017, BPL-003, COMP360 (Psilocybin), AXS-05, FALKIERI (esketamine DPI), and others
• Treatment Resistant Depression Therapeutic Assessment: Treatment Resistant Depression current marketed and Treatment Resistant Depression emerging therapies
• Treatment Resistant Depression Market Dynamics: Treatment Resistant Depression market drivers and Treatment Resistant Depression market barriers

Request for Sample PDF Report for Treatment Resistant Depression Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/treatment-resistant-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Treatment Resistant Depression Report Introduction
2. Treatment Resistant Depression Executive Summary
3. Treatment Resistant Depression Overview
4. Treatment Resistant Depression- Analytical Perspective In-depth Commercial Assessment
5. Treatment Resistant Depression Pipeline Therapeutics
6. Treatment Resistant Depression Late Stage Products (Phase II/III)
7. Treatment Resistant Depression Mid Stage Products (Phase II)
8. Treatment Resistant Depression Early Stage Products (Phase I)
9. Treatment Resistant Depression Preclinical Stage Products
10. Treatment Resistant Depression Therapeutics Assessment
11. Treatment Resistant Depression Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Treatment Resistant Depression Key Companies
14. Treatment Resistant Depression Key Products
15. Treatment Resistant Depression Unmet Needs
16 . Treatment Resistant Depression Market Drivers and Barriers
17. Treatment Resistant Depression Future Perspectives and Conclusion
18. Treatment Resistant Depression Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Treatment Resistant Depression Market https://www.delveinsight.com/report-store/treatment-resistant-depression-trd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Treatment Resistant Depression Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Treatment Resistant Depression Epidemiology https://www.delveinsight.com/report-store/treatment-resistant-depression-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Treatment Resistant Depression Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Ventricular Assist Devices Market https://www.delveinsight.com/report-store/ventricular-assist-devices-vad-market
Ventricular Assist Devices Market By Product Type (Left Ventricular Assist Devices, Right Ventricular Assist Devices, And Biventricular Assist Devices), By Application Type (Bridge-To-Transplant [Btt], Destination Therapy, And Others), By Design Type (Transcutaneous Ventricular Assist Devcies And Implantable Ventricular Assist Devices), By Type Of Flow (Pulsatile Flow And Continous Flow), By End User (Hospital And Clinics, Ambulatory Surgical Centers, And Others), by geography is expected to grow at a steady CAGR forecast till 2028 owing to the increasing prevalence of heart failure and cardiovascular diseases due to obesity, age, & unhealthy lifestyles and rising demand for organ transplants due to increasing prevalence of chronic ailments such as hypertension, diabetes, and others

B-cell Non-hodgkin Lymphoma Market https://www.delveinsight.com/report-store/b-cell-non-hodgkin-lymphoma-market
DelveInsight's "B-Cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the B-Cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-Cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Systemic Sclerosis Market
https://www.delveinsight.com/report-store/systemic-sclerosis-market
DelveInsight's "Systemic Sclerosis Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Systemic Sclerosis. The report includes a detailed examination of the historical and projected epidemiology data that includes diagnosed prevalent cases of Systemic Sclerosis segmented by gender-specific, age-specific, and type-specific cases.

Resorbable Vascular Scaffold Market
https://www.delveinsight.com/report-store/resorbable-vascular-scaffolds-market
"DelveInsight's 'Resorbable Vascular Scaffolds Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Resorbable Vascular Scaffolds and the historical and forecasted Resorbable Vascular Scaffolds market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vascular Stents Market
https://www.delveinsight.com/report-store/vascular-stents-market
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2030 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Bladder Scanners Market
https://www.delveinsight.com/report-store/bladder-scanners-market
"DelveInsight's 'Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Vein Illumination Devices Market
https://www.delveinsight.com/report-store/vein-illumination-devices-market
"DelveInsight's 'Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2028' report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Ventilator Market
https://www.delveinsight.com/report-store/ventilators-market
Ventilators Market By Mobility (Intensive Care Ventilators, Portable/Transportable Ventilators), By Type (Adult/Pediatric Ventilators, Neonatal/Infant Ventilators), By Interface (Invasive Ventilation, Non-Invasive Ventilation), By End-User (Hospitals, Home Care, Ambulatory Surgical Centers, Others), By Geography is expected to grow at a steady CAGR forecast till 2030 owing to launch of advanced devices and increasing prevalence of respiratory diseases such as COPD.

Vascular Graft Devices Market
https://www.delveinsight.com/report-store/vascular-grafts-market
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2030 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2030 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products.

Symptomatic Partial-thickness Rotator Cuff Tears Market
https://www.delveinsight.com/report-store/symptomatic-partial-thickness-rotator-cuff-tears-market
DelveInsight's "Symptomatic Partial-thickness Rotator Cuff Tears Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Symptomatic Partial-thickness Rotator Cuff Tears, historical and forecasted epidemiology as well as the Symptomatic Partial-thickness Rotator Cuff Tears market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market
https://www.delveinsight.com/report-store/zika-virus-market
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.